NIRFLI with ICG
PreclinicalSmall molecule
NIRFLI with ICG is one of 27 small molecule programs targeting Tic Disorder. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
26
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
26 competitors in Tic Disorder
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Zofran
NovartisApproved
Zyprexa
MMODAG GmbH
Approved
Clozaril
LLife Extension Foundation Inc.
Approved
Reminyl
WWim Janssens
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Intuniv
PPromius Pharma, LLC
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Balversa
Johnson & JohnsonPhase 2
Rituxan
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tic Disorder1 trial
Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders
Enrolling by invitation·TThe University of Texas Health Science Center, Houston··NCT00833599·283 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NIRFLI with ICG. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details